Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial

  1. O. Chosidow,
  2. Y. Drouault,
  3. F. Leconte-Veyriac,
  4. M. Aymard,
  5. J.P. Ortonne,
  6. F. Pouget,
  7. J. Revuz,
  8. J.M. Decazes,
  9. J.E. Malkin

Article first published online: 22 AUG 2002

DOI: 10.1046/j.1365-2133.2001.04139.x

Issue

British Journal of Dermatology

British Journal of Dermatology

Volume 144, Issue 4, pages 818–824, April 2001

Additional Information

How to Cite

Chosidow, O., Drouault, Y., Leconte-Veyriac, F., Aymard, M., Ortonne, J., Pouget, F., Revuz, J., Decazes, J. and Malkin, J. (2001), Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. British Journal of Dermatology, 144: 818–824. doi: 10.1046/j.1365-2133.2001.04139.x

Author Information

  1. Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Université Paris VI, 47–83 bd de l’Hôpital, 75013 Paris, France *Department of Dermatology, Groupe Hospitalier Cochin-Saint Vincent de Paul, Paris, France †Department of Biostatistics, Lincoln Systems, Boulogne Billancourt, France ‡Department of Virology, Domaine Rockefeller, Lyon, Paris, France §Department of Dermatology, Hopital l’Archet-2, Nice, France ¶Department of Dermatology, Hopital Henri Mondor, Créteil, France **Department of Infectious Diseases, Hopital Saint-Louis, Paris ††The Department of Infectious Diseases, Institut Alfred Fournier, Paris

* O. Chosidow. E-mail: olivier.chosidow@psl.ap-hop-paris_fr

Publication History

  1. Issue published online: 22 AUG 2002
  2. Article first published online: 22 AUG 2002
  3. Accepted for publication 25 October 2000

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (297K)

Keywords:

  • aciclovir;
  • famciclovir;
  • recurrent genital herpes

Background Twice-daily therapy with famciclovir (FCV) was shown to be effective for episodic therapy for recurrent genital herpes in a large placebo-controlled trial. However, no study has been published to date comparing FCV and aciclovir (ACV).

Objectives We have evaluated the effectiveness of FCV vs. ACV in the treatment of recurrent genital herpes infection.

Methods A multicentre, double-blind, double-placebo, randomized, parallel-design study, assessed for equivalence, was conducted. As the analysis was based on confidence intervals, a difference of lesion healing time between ACV and FCV (Δ) of 1·05 days with a standard deviation of 2·30 days was chosen. Two hundred and four outpatients were included. Patients self-initiated oral therapy with 125 mg of FCV twice daily or ACV 200 mg five times daily for 5 days. The principal end-point of the study was the complete healing of lesions. Duration of the complete resolution of all symptoms, and safety were also considered.

Results The mean healing time was 5·1 days and 5·4 days for FCV and ACV, respectively, with a crude value of Δ = 0·25 days (CI 95%: −0·32; 0·82) in the intent-to-treat population. Therefore, the confidence interval for the difference between the two treatments lies entirely within the equivalence range (−1·05–1·05). The value of Δ in the per-protocol population [0·35 day (CI 95%: −0·24; 0·93)] was comparable between the two groups. No differences were detected in the proportion of patients having complete healing at the different days of evaluation as well as in the duration until the complete resolution of all the symptoms. The frequency, nature and severity of adverse events did not differ among the two treatment groups.

Conclusions Twice-daily FCV was as effective and safe in the treatment of recurrent genital herpes simplex virus infection as five times daily ACV.

View Full Article (HTML) Get PDF (297K)